Literature DB >> 24738666

Using a drug-safety tool to prevent competition.

Ameet Sarpatwari1, Jerry Avorn, Aaron S Kesselheim.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24738666     DOI： 10.1056/NEJMp1400488

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Regulation of the pharmaceutical industry: promoting health or protecting wealth?

Authors:  Alan Maynard; Karen Bloor
Journal:  J R Soc Med       Date:  2015-04-28       Impact factor: 5.344

2.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875

3.  Methodological approaches to evaluate the impact of FDA drug safety communications.

Authors:  Aaron S Kesselheim; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; John D Seeger; John S Brownstein; Steven Woloshin; Lisa M Schwartz; Timothy Toomey; Gerald J Dal Pan; Jerry Avorn
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

Review 4.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

Review 5.  The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose.

Authors:  Leo Beletsky
Journal:  Am J Prev Med       Date:  2014-12-26       Impact factor: 5.043

6.  The Prescription Drug User Fee Act: Much More Than User Fees.

Authors:  Aaron P Mitchell; Niti U Trivedi; Peter B Bach
Journal:  Med Care       Date:  2022-04-01       Impact factor: 2.983

7.  Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.

Authors:  Irene B Murimi-Worstell; Jeromie M Ballreich; Marissa J Seamans; G Caleb Alexander
Journal:  PLoS One       Date:  2019-11-12       Impact factor: 3.240

8.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

9.  Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.

Authors:  Ameet Sarpatwari; Beatrice L Brown; Sarah A McGraw; Sara Z Dejene; Abdurrahman Abdurrob; Adrian J Santiago Ortiz; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2022-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.